Treatment Efficacy

Among patients with pulmonary arterial hypertension treated with 72-week seralutinib, those deemed responders had more improved measures, according to a poster presented at the Pulmonary Vascular Research Institute 2025 Annual Congress.

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut allergy was not achieved, according to results published in Allergy.

Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally tolerated it well, according to data published in The Lancet Respiratory Medicine.

INDIANAPOLIS — A single spray of MydCombi administered via the Optejet dispenser was comparable in efficacy to the label recommendation of two sprays in inducing clinically relevant mydriasis, according to researchers at Academy 2024.

Aviceda Therapeutics has completed enrollment of its phase 2b SIGLEC study, which will compare the safety and efficacy of AVD-104 vs. Izervay in patients with geographic atrophy secondary to age-related macular degeneration.

Receiving itepekimab led to a 51% lower adjusted annualized exacerbation rate in former smokers with moderate/severe COPD and exacerbation history, according to a poster presented at the European Respiratory Society International Congress.

SAN DIEGO — Among patients with pulmonary arterial hypertension, seralutinib lowered pulmonary vascular resistance over 72 weeks, according to research presented at the American Thoracic Society International Conference.

Patients with non-cystic fibrosis bronchiectasis experienced less FEV1 and FVC decline and had improved quality of life with 52-week once-daily brensocatib vs. placebo, according to findings presented at the World Bronchiectasis Conference.

Although inhaled antisense oligonucleotide treatment is safe, its efficacy needs to be determined in patients with the cystic fibrosis splicing mutation 3849+10kb C-to-T, according to a press release from the Cystic Fibrosis Foundation.

SAN DIEGO — Bisoprolol treatment yielded a similar yearly rate of COPD exacerbations that require oral corticosteroids and/or antibiotics to placebo, according to research presented at the American Thoracic Society International Conference.